ADOPTION OF NALTREXONE BY CLINICAL PROVIDERS

最近的科学研究已经产生了新的药物， 改善酒精滥用和依赖治疗的潜力。然而，在这方面， 除非这些新药被治疗界接受， 它们改善成果的潜力将无法实现。 临床医生 最近被批准为第一个新的 治疗酒精中毒的药物。 本研究 研究了酒精中毒治疗临床医生对纳洛酮的采用情况， 在不同的环境中，以确定鼓励或阻碍其 收养作为治疗的辅助手段。 酒精中毒治疗临床医生（医生和非医生 临床医生）在三个州（马萨诸塞州，华盛顿州， 田纳西州）将调查他们对纳洛酮的接受程度， 以及其他药物治疗。 多元 logit分析将用于估计个体效应 临床医生特征，其治疗设置的特征， 并说明采用或不采用纳洛酮的地点， 临床医生这将支持对以下方面差异的实证评估： 医生和非医生临床医生采用纳洛酮，以及 由那些在公共和私营部门，在管理式护理实践， 和其他设置，以及在不同状态的治疗环境中。 数据 由制造商提供的销售纳洛酮将用于 提供背景内容。第二来源将补充调查 关于临床医生执业的组织和国家的数据 治疗环境 随着越来越多的药物被开发用于治疗酒精和其他疾病， 需要提供关于吸毒的障碍和促进因素的信息， 他们被临床医生采用。 这项研究将记录和解释 接受这种药物的模式，以告知战略， 传播未来的治疗创新。

Recent scientific research has generated new medications with the potential to improve treatment of alcohol abuse and dependence. However, unless these new medications are accepted by the treatment community, their potential to improve outcomes will not be realized. Clinicians have been slow to adopt naltrexone, recently approved as the first new medication for alcoholism treatment in forty years. This research studies the adoption of naltrexone by alcoholism treatment clinicians in different settings to identify factors that encourage or impede its adoption as an adjunct in treatment. Alcoholism treatment clinicians (both physicians and non-physician clinicians) in three states (Massachusetts, Washington State, and Tennessee) will be surveyed regarding their acceptance of naltrexone as well as other pharmacological therapies in treatment. Multivariate logit analysis will be used to estimate the effect of individual clinician characteristics, characteristics of their treatment settings, and state location on the adoption or non-adoption of naltrexone by clinicians. This will support empirical assessment of differences in adoption of naltrexone by physician and non-physician clinicians, and by those practicing in the public and private sector, in managed care and other settings, and in different state treatment environments. Data on sales of naltrexone provided by the manufacturer will be used to provide background context. Secondary sources will supplement survey data regarding organizations in which clinicians practice and the state treatment environment. As more pharmaceuticals are developed for treatment of alcohol and other addictions, information is needed on barriers to and facilitators of their adoption by clinicians. This research will document and explain patterns of acceptance of such medications to inform strategies for dissemination of future treatment innovations.